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Abstract
Viral gene therapy against malignant tumors holds great
promise for tumors that are susceptible to the oncolytic
activity of viruses. One advantage of oncolytic viral
therapy is that it can potentially be combined with other
therapies, such as radiotherapy, to obtain an enhanced
tumor response. In the case of prostate cancer, herpes
simplex virus–mediated therapies have been shown to
be highly effective in animal models; however, studies
of the efficacy of combined viral and radiation therapy
have not yet been reported. In this study, we have
combined G207, a multimutated HSV type 1 vector, with
external beam radiation therapy of prostate tumors
grown subcutaneously in mice. We examined both the
human LNCaP tumor in athymic mice and the mouse
transgenic TRAMP tumor in either athymic mice or its
syngeneic host, C57BL/6 mice. Virus was delivered
either intravenously, in the case of LNCaP, or intra-
tumorally, in the case of TRAMP. We found that
individually, either G207 or radiation was effective in
delaying tumor growth in these models. However,
delivering the treatments simultaneously did not pro-
duce an enhanced effect. Neoplasia (2001) 3, 451–456.
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Introduction
The use of replication-competent viruses for tumor therapy
is a promising strategy that has progressed to early clinical
trials [1–5]. Replication-competent or conditionally replicat-
ing herpes simplex virus type 1 (HSV-1) vectors have been
generated by mutating genes involved in viral DNA synthesis
and/or virulence in order to target viral replication and toxicity
to tumor cells [6,7 ]. G207 is a multimutated HSV-1 vector
that lacks both copies of the ICP34.5 gene, a gene required
for neurovirulence, and contains an insertion of the lacZ gene
inactivating the ICP6 gene, encoding the large subunit of
ribonucleotide reductase [8]. Studies in both human xeno-
graft and syngeneic mouse tumor models have demonstra-
ted the value of HSV-based therapies in terms of both
growth inhibition and cures [9]. These findings await
confirmation in human clinical trials.
One advantage of viral gene therapy is that it can
potentially be combined with other therapies to obtain an
enhanced tumor response. In fact, recent reports about
combination viral / radiotherapy and viral /chemotherapy in
glioma and head and neck cancer animal models suggest
that this may be a viable approach [10–15]. Human
prostate tumor cells are particularly sensitive to HSV-1
vectors [16], and this has led to experimental treatment
strategies that deliver mutated viruses by either intra-
tumoral or intravenous injection. However, studies on the
efficacy of combined viral and radiotherapy have not been
reported. In this study, we assess the ability of radiation
to affect the activity of G207 against prostate cancer.
G207 treatment was combined with external beam
radiation therapy of prostate cancer grown subcutane-
ously in mice. We used both the LNCaP human tumor in
athymic mice and the transgenic TRAMP mouse tumor in
either athymic mice or its syngeneic host, C57BL/6 mice.
Virus was delivered either intravenously, in the case of
LNCaP, or intratumorally, in the case of TRAMP. We
found that G207 and radiation were each effective in
producing growth delay in these models, but simulta-
neously delivering the treatments did not produce an
enhanced effect.
Materials and Methods
Cell Lines and Culture Conditions
The human prostate cancer cell line LNCaP (Georgetown
University Medical Center, Lombardi Cancer Center Tissue
Culture Shared Resource, Washington, DC) was maintained
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in RPMI 1640 (Biofluids) containing 10% fetal bovine serum
(Life Technologies, Grand Island, NY). The TRAMP-C2
mouse prostate cancer cell line [17] was grown in DMEM
high glucose (DMEM-HG; Life Technologies) supple-
mented with 5% fetal bovine serum (Life Technologies),
5% Nu-serum IV (Collaborative Biomedical Products, Bed-
ford, MA), 5g/ml bovine insulin (Life Technologies), and
108 M dihydrotestosterone (Sigma Chemical, St. Louis,
MO). Penicillin–streptomycin (Mediatech, Herndon, VA)
and L-glutamine (Mediatech) were added to each culture
and the cells were maintained at 378Cwith 5% CO2. Both cell
lines were confirmed to be free of mycoplasma contami-
nation.
Preparation and Injection of Cells into Animals
Four- to 6-week-old C57BL/6 black or NCRNU athymic
male mice were obtained from Harlan Laboratories ( Indian-
apolis, IN) or Taconic Laboratories (Germantown, NY),
respectively. All animals were quarantined for 1 week before
the study and allowed access to food and water ad libitum.
The animals were anesthesized by intraperitoneal injection
of 0.15 to 0.2 ml of 10% sodium pentobarbital (Abbott
Laboratories, North Chicago, IL) in bacteriostatic saline
(0.9% sodium chloride; Abbott Laboratories) with 6% ethyl
alcohol. C57BL/6 mice were shaved in the rump before
injections. Cells, 1107, in 0.1 ml were injected subcuta-
neously in the sacral region of each animal to induce tumors
in the TRAMP experiments. For the LNCaP experiments, the
cells (1107) were first mixed with an equal volume of
Matrigel (Collaborative Biochemical Products) and then
injected. Tumors were measured twice weekly by calipers
to within 0.5 mm, and volumes were calculated (V=HLW )
and recorded. Animals were randomized into treatment
groups once their tumor size was in the range of 100 to 320
mm3. After tumor cell injection, LNCaP tumors took 5 to 6
weeks to grow to treatment size, whereas TRAMP tumors
grew in 1 to 3 weeks. In the LNCaP experiment, animals
were given G207 (2107 pfu) by tail vein injection on days 0
and 4, and irradiated on days 1 to 5. In both TRAMP
experiments, animals were given G207 (2107 pfu) intra-
tumorally on days 0, 3, and 6, and irradiated daily on days
1 to 5. On days with both virus injection and irradiation, the
virus was given to the animals before the irradiation
occurred. The animal procedures described here were
approved by the Georgetown University Animal Care and
Use Committee.
Irradiation of Prostate Tumors LNCaP and TRAMP
A 137Cs Shepherd Mark I irradiator was used to irradiate
the tumors in the sacral region of the animal. The mice
were restrained in clear plastic holders with a lead cover,
which contains a port through which the radiation can enter
to irradiate the tumor. The holders were placed behind a
lead wall, which shields the mouse’s body, exposing the
irradiation port of the holder above the edge of the wall.
Four animals were irradiated simultaneously. Doses to the
tumor under this geometry were confirmed using a phantom
mouse and thermoluminescent dosimetry. In the LNCaP
experiment, the tumors were given 10 Gy fractionated over
days 1 to 5 ( i.e., 2 Gy/day). In the TRAMP experiments,
the tumors were given a total of 20 Gy over days 1 to 5
( i.e., 4 Gy/day).
Clonogenic Cell Survival Curves
Logarithmically growing cells were harvested and seeded
into tissue culture flasks at various cell numbers depending
upon the radiation dose which the flask was to receive ( i.e.,
more cells for higher doses), so that the final number of
survivors in each flask would be similar. After allowing time
for attachment, the flasks were irradiated to various doses
and returned to the incubator for 2 weeks. The flasks were
stained to reveal colonies produced from the clones of
surviving cells and counted. The fraction of survivors relative
to the original number of cells seeded was calculated and
then normalized to the zero-dose plating efficiency to
determine the surviving fraction at each dose. The data
were fitted to the single-hit multitarget curve model [18].
Results
Human LNCaP Tumor Treatment
LNCaP is a commonly used hormone-responsive human
prostate cell line that grows well, albeit slowly, as subcuta-
neous tumors in athymic mice [19]. LNCaP tumor cells are
particularly sensitive to G207, both in vitro and in vivo [16].
The LNCaP tumor is wild type for p53 and secretes prostate-
specific antigen [19]. Its cellular radioresponses have been
characterized for both clonogenic survival and apoptosis
[20–23]. Because the LNCaP/athymic mouse xenograft
model has been prevalent and important in prostate cancer
research [24], we chose this as one of our models for
studying combined radiation/G207 effects.
We previously found LNCaP tumors to be highly sensitive
to intratumorally and intravenously injected G207 [16]. Even
a single intratumoral injection of G207 (2107 pfu) caused a
major reduction in tumor volumes with complete eradication
of 25% of the tumors. This viral response was too great for
combined radiation/viral studies, where partial responses for
each agent are needed to assess potential interactions.
Even when the viral titers were lowered to 105 pfu, significant
cures ensued (data not shown). For this reason, we decided
to employ intravenous treatment with G207, which we knew
gave a less robust treatment response [16]. We employed
two intravenous injections spread over 4 days, and combined
it with five daily fractions of radiation, starting on the day after
the first viral treatment.
Radiation therapy was effective at inhibiting tumor growth
(Figure 1 ); however, the irradiated tumors grew back
relatively quickly. In contrast, volumes of G207- treated
tumors were markedly reduced and regrowth occurred much
more slowly than for irradiated tumors (Figure 1 ). Never-
theless, by 40 days, all of the tumors had started to grow
back. For the combined radiation and G207 treatment,
tumors regressed slightly faster than for G207 alone, but
ultimately reached the same minimum volume — again on
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day 40 — at which point they began to regrow at a rate that
was indistinguishable from G207 treatment alone (Figure 1 ).
Nadir tumor volumes were statistically significantly different
at P<.05 between all treatment groups, except for radiation
plus G207 versus G207 alone, which were not significantly
different from each other. There were no cures in any of the
groups.
Murine TRAMP Tumor Treatment
TRAMP represents a relatively new animal model for
prostate cancer research [17,25]. In this syngeneic mouse
model, transgenic mice carry the SV40 large tumor antigen
linked to a prostate-specific promoter. Expression of the
transgene in prostate tissue caused tumors to arise in situ at
about 8 weeks of age, and these tumors resembled naturally
arising prostate cancer. Several tumor cell lines have been
established in tissue culture from the prostate tumors of
TRAMP mice. These tumor lines no longer express large T
antigen [17].
TRAMP tumor cell lines grow very well subcutaneously
in either athymic mice or in the syngeneic parental mice,
C57BL/6, from which the TRAMP transgenic mice were
derived. This feature of the model provided major
advantages because G207 treatment of murine tumors in
syngeneic mice leads to a potent antitumor immune
response [26,27]. The TRAMP tumor model allows us to
examine the effect of the immune system on both
treatment strategies and their combination by comparing
efficacy in immunocompromised and immunocompetent
mice.
The TRAMPmodel system is not as well characterized for
radiation responses as LNCaP; however, it is known to be
wild type for p53, like LNCaP [17]. We were able to confirm
the p53 phenotype by showing radiation induction of the p53
transcriptionally activated p21WAF1 /CIP1 protein in both
LNCaP and TRAMP cells in vitro (data not shown).
Preliminary studies with subcutaneous TRAMP tumors
suggested that they were twice as resistant to radiation
therapy compared to LNCaP. This was consistent with in
vitro clonogenic cell survival curve analysis (Figure 2 ),
suggesting that the tumor resistance of TRAMP was an
intrinsic property of the cells, and not due to possible tumor
physiology differences. Hypoxia, for example, has been
reported to affect tumor radioresponses in other prostate
cancer animal models [28]. Due to the greater radio-
resistance of TRAMP tumors, 20 Gy was used for the
therapy dose, rather than the 10 Gy that was used for
LNCaP.
Mouse tumor cells, in general, are less susceptible to
G207 replication and cytotoxicity than human tumor cells.
Growth curves for untreated TRAMP tumors in athymic mice
showed that they grow twice as fast as LNCaP tumors, and
the delay produced by G207 was much less than that for
LNCaP (Figure 3 ). TRAMP tumors treated with radiation
Figure 2. Radiation survival curves for TRAMP and LNCaP cells. Points
represent the mean of four independent experiments, each performed on
different days; bars represent the standard deviation of the means. The data
were fitted to the single -hit multitarget survival model and D0 and Dq
parameters, respectively, measured in Gy, for each cell line, which were as
follows: Tramp, 1.763 and 1.219; LNCaP, 1.015 and 1.631.
Figure 1. Mean relative volumes of LNCaP prostate tumors in athymic male
mice. The mean relative tumor volumes, compared to the first day of
treatment, of tumor - bearing mice treated with virus buffer (Controls ), G207,
irradiation (RT ), or both (RT+G207 ). Irradiated animals were treated for days
1 to 5 of the experiment with 2 -Gy daily fractions for a total dose of 10 Gy.
Virus - treated animals were given virus at 2107 pfu by tail vein injection on
days 0 and 4 of the experiment. Each point represents the mean tumor
volume±1 SEM. In some cases where individual animals were sacrificed due
to large tumor burden, the tumor size at the time of sacrifice was used for
subsequent calculations of mean tumor volume.
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therapy alone produced about twice the growth delay of
G207 alone. Combined radiation and G207 produced no
greater delay than radiation therapy alone.
In order to assess the possible influence of an intact
immune system in the TRAMP response to G207 and
radiation, the TRAMP tumor experiment was also conducted
in C57BL/6 mice (Figure 4 ). Compared to the athymic
mouse host, G207 was much more effective in inhibiting
TRAMP tumor growth in C57BL/6 mice (Figure 3 versus
Figure 4 ). In fact, the G207 delay was now greater than the
delay for radiation alone. This increased efficacy of G207 in
syngeneic mouse models is consistent with results obtained
with CT26 colon carcinoma in BALB/c mice, N18 neuro-
blastoma in A/J mice, and M3 melanoma in DBA/2 mice
[26,27], suggesting that immune responses contribute to the
antitumor activity of G207.
In contrast to the G207 response, tumor growth with
radiation alone was similar in athymic and C57BL/6 mice,
suggesting that the immune system was not affecting
TRAMP tumor regression caused by radiotherapy. Although
tumor radioresponses are largely thought to be driven by
intrinsic properties of tumors [29], recently it has been
reported that T cells and natural killer cells may promote
radiotherapy tumor regression in some tumors [30]. Never-
theless, in our model, the presence or absence of a thymus
did not affect tumor radioresponse, and the combined
radiation and G207 treatment produced no greater tumor
delay than the best single therapy alone in either host. Also,
an interaction between G207 and radiation treatment was
not seen for the TRAMP tumor regardless of the host strain.
Discussion
It has been reported that the efficacy of therapeutic HSV-1
R3616 against subcutaneous and intracranial human U87
malignant glioma xenografts in athymic mice is significantly
enhanced by radiation [10,13]. Similar findings were
reported for HSV-1 R7020 against subcutaneous human
head and neck cancer cell line, SQ20b [11]. In the current
study, G207, another therapeutic herpes vector, is evaluated
for combination therapy against prostate cancer. When the
combination of G207 and radiation did not enhance efficacy
in the TRAMP syngeneic tumor model, we hypothesized that
this might be due to species differences or the effect of
cellular immunity. Therefore, we examined a human xeno-
graft in athymic mice, as was the case in the studies of
Advani et al. [10,11] and Bradley et al. [13 ]. In neither a
human nor a mouse tumor model system was there a benefit
from combining radiation with G207.
In our experiments, radiation treatments were fractio-
nated over five consecutive days ( i.e., experimental days 1
to 5). We find that this fractionation regimen is amenable to a
wide variety of subcutaneous tumor models, regardless of
differences in tumor growth rates or intrinsic cellular radio-
sensitivities, and it allows easier cross comparisons between
Figure 3. Mean relative volumes of TRAMP prostate tumors in athymic male
mice. The mean relative tumor volumes, compared to the first day of
treatment, of tumor - bearing mice treated with virus buffer (Controls ), G207,
irradiation (RT ), or both (RT+G207 ). Irradiated animals were treated for days
1 to 5 of the experiment with 4 -Gy daily fractions for a total dose of 20 Gy.
Virus - treated animals were given virus at 2107 pfu by intratumoral injections
on days 0, 3, and 6 of the experiment. Each point represents the mean tumor
volume±1 SEM. In some cases where individual animals were sacrificed due
to large tumor burden, the tumor size at the time of sacrifice was used for
subsequent calculations of mean tumor volume.
Figure 4. Mean relative volumes of TRAMP prostate tumors in male C57BL /6
mice. The mean relative tumor volumes, compared to the first day of
treatment, of tumor - bearing mice treated with virus buffer (Controls ), G207,
irradiation (RT ), or both (RT+G207 ). Irradiated animals were treated for days
1 to 5 of the experiment with 4 -Gy daily fractions for a total dose of 20 Gy.
Virus - treated animals were given virus at 2107 pfu by intratumoral injections
on days 0, 3, and 6 of the experiment. Each point represents the mean tumor
volume±1 SEM. In some cases where individual animals were sacrificed due
to large tumor burden, the tumor size at the time of sacrifice was used for
subsequent calculations of mean tumor volume.
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the radioresponses of tumors because the number and
timing of fractions are always constant. For intratumoral
injections, we used three injections, timed to be before (day
0), during (day 3), and after (day 6) radiation therapy, in
order to help ensure that we would cover all possible
temporal sensitivity windows for radiation/virus interactions.
For intravenous injections, we injected on days 0 and 4
because we had previously shown that this injection regimen
worked well with LNCaP tumors [16]. It was not our intention
to directly duplicate the protocols of Advani et al. [10,11] and
Bradley et al. [13] because different experimental regimens
were used in each of their three publications, and no
particular protocol appeared to be critical. Also, because
radiation treatments with different doses and fractionation
schemes were seen to enhance the antitumor activity of both
R7020 and R3616 on glioma and carcinoma, we did not
expect that it would be necessary to exactly imitate a
particular treatment regimen in order to see an effect with
G207. Furthermore, Advani et al. and Bradley et al. did not
directly compare the effect of different time delays of
irradiation postinfection; however, in the one study where
different delays were used, there were no indications that a
shorter time (4 hours) was better than a longer delay (24
hours). Therefore, we do not believe that the failure of
radiation and G207 to act synergistically or additively in our
prostate tumor models can be attributed merely to minor
temporal differences between virus and irradiation treat-
ments. Rather, it is more likely that differences in tumor type
and biology play a role in the phenomenon reported by
Advani et al. and Bradley et al.
Despite the fact that the combination of G207 and
radiation did not enhance the tumor response over the most
effective individual therapy, there are several findings that
are important for designing tumor therapy. The TRAMP
tumor maintained the same radiosensitivity in either the
athymic or immunocompetent host. This was expected
because immune responses are not thought to be a major
factor in tumor radioresponses [30]. G207, however, worked
worse than radiation in athymic mice, but better than
radiation in C57BL/6 mice. This illustrates the dual factors
contributing to the viral antitumor response — direct
oncolytic activity and induction of tumor-specific immune
responses.
Although radiation did not sensitize the tumors to virus,
it also did not decrease the efficacy of the virus either.
These results, combined with our earlier published results
[16] indicating that tumors that recurred following radiation
therapy remained sensitive to virus, suggest that G207
therapy might be a useful therapy for tumors that recur in
the radiation field. Also, because localized radiotherapy
would not result in systemic immunosuppression, it is less
likely than chemotherapy to interfere with subsequent
immune-mediated tumor cell killing by G207. Along these
lines, intravenous administration of herpes virus following
irradiation might have the added benefit of targeting
metastases that local radiation therapy alone cannot reach.
Conversely, these results suggest that little benefit is
derived from delivering both treatments simultaneously.
Because the radiation adds little to the cytotoxicity of
prostate tumors produced by the virus alone, delivering
radiation at the time of viral treatment might even preclude
later use of radiotherapy to treat recurring local disease.
These results, taken together with our earlier findings that
recurring irradiated tumors remained fully sensitive to G207
[16], suggest that sequential, rather than simultaneous,
treatment with radiation followed by G207 may produce the
best results in terms of delaying tumor regrowth and
prolonging survival.
The discrepancy between these findings in prostate and
those previously reported with glioma and head and neck
cancer may reflect more than simple tumor type differences.
R3613 and R7020 are more virulent viruses that replicate
better than G207. If, as the previous investigators suggest,
the enhanced effect is due to increased viral replication in
irradiated cells [10] — possibly as the result of host cell
DNA damage [31] — then viruses with a high replication
capacity might be better able to capitalize on this. Alter-
natively, the relatively high sensitivity of prostate tumors to
G207 herpes virus [16] may mean that they are already fully
sensitized to the cytotoxic effects of the virus, and irradiation
cannot further enhance killing by virus. Regardless, our
findings suggest that tumor sensitization to herpes viral
therapy by radiation is not a universal phenomenon, and that
both viral - and tissue-specific factors may be strong
determinants of the effect, and warrant further study.
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